Datasheet

生物学的記述

Specificity	ApoA5 Antibody [H10J23] detects endogenous levels of total ApoA5 protein.
Background	ApoA5 (apolipoprotein A-V) is a hydrophobic, amphipathic 343-amino-acid protein in the apolipoprotein gene family (APOA1/C3/A4 cluster) and serves as a crucial regulator of plasma triglyceride levels, particularly on triglyceride-rich lipoproteins such as chylomicrons and VLDL. ApoA5 features an N-terminal water-soluble helix bundle (residues 1–146), a C-terminal lipid-binding domain (295–343), and a proteoglycan-binding site (186–227) that facilitates interactions with lipoproteins and the endothelium, with coiled-coil domains enhancing lipid droplet and endothelial binding. ApoA5 binds triglyceride-rich lipoproteins and recruits lipoprotein lipase (LPL) via GPIHBP1 on capillary endothelial cells, stabilizing the lipolytic complex in membrane subdomains to accelerate chylomicron and VLDL lipolysis, and also suppresses ANGPTL3/8-mediated LPL inhibition through its C-terminal region. Within hepatocytes, ApoA5 targets ER-localized lipid droplets to regulate hepatic triglyceride flux, directing cytosolic lipid droplet formation over secretion and influencing lipoprotein assembly. Loss-of-function mutations or polymorphisms in APOA5 impair lipolysis and remnant clearance, leading to hypertriglyceridemia and increased cardiovascular risk.

Specificity

ApoA5 Antibody [H10J23] detects endogenous levels of total ApoA5 protein.

Background

ApoA5 (apolipoprotein A-V) is a hydrophobic, amphipathic 343-amino-acid protein in the apolipoprotein gene family (APOA1/C3/A4 cluster) and serves as a crucial regulator of plasma triglyceride levels, particularly on triglyceride-rich lipoproteins such as chylomicrons and VLDL. ApoA5 features an N-terminal water-soluble helix bundle (residues 1–146), a C-terminal lipid-binding domain (295–343), and a proteoglycan-binding site (186–227) that facilitates interactions with lipoproteins and the endothelium, with coiled-coil domains enhancing lipid droplet and endothelial binding. ApoA5 binds triglyceride-rich lipoproteins and recruits lipoprotein lipase (LPL) via GPIHBP1 on capillary endothelial cells, stabilizing the lipolytic complex in membrane subdomains to accelerate chylomicron and VLDL lipolysis, and also suppresses ANGPTL3/8-mediated LPL inhibition through its C-terminal region. Within hepatocytes, ApoA5 targets ER-localized lipid droplets to regulate hepatic triglyceride flux, directing cytosolic lipid droplet formation over secretion and influencing lipoprotein assembly. Loss-of-function mutations or polymorphisms in APOA5 impair lipolysis and remnant clearance, leading to hypertriglyceridemia and increased cardiovascular risk.

使用情報

Application

WB, IP

Dilution

WB	IP
1:1000	1:50

Reactivity

Human

Source

Mouse Monoclonal Antibody

MW

41 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/23307945/
https://pubmed.ncbi.nlm.nih.gov/26028042/

ApoA5 Antibody [H10J23]

生物学的記述

使用情報

References

Application Data